CSF1R and breast carcinoma: Experimental studies also demonstrated that BLZ945, a highly selective small molecule CSF-1R inhibitor, not only inhibits monocyte recruitment into murine breast cancer by 6-fold but may also increase the infiltration of CTLs in cervical and breast carcinomas, relieving immunosuppression [11, 79].